Clinical Trial Update: Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 randomized trial comparing CP-675,206 to best supportive care after platinum-based therapy in non-small-cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CP-675,206

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-small-cell Lung | Phase 2 | Status: COMPLETED